TITLE

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

AUTHOR(S)
Jihyung Hong; Dilla, Tatiana; Arellano, Jorge
PUB. DATE
January 2009
SOURCE
BMC Psychiatry;2009, Vol. 9, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3-6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day oral dosing. This study aims to estimate the cost-effectiveness of atomoxetine compared to MPH. In addition, atomoxetine is compared to 'no medication' for patient populations who are ineligible for MPH (i.e. having stimulant-failure experience or co-morbidities precluding stimulant medication). Methods: An economic model with Markov processes was developed to estimate the costs and benefits of atomoxetine versus either MPH or 'no medication'. The incremental cost per quality-adjusted life-year (QALY) was calculated for atomoxetine relative to the comparators. The Markov process incorporated 14 health states, representing a range of outcomes associated with treatment options. Utility values were obtained from the utility valuation survey of 83 parents of children with ADHD. The clinical data were based on a thorough review of controlled clinical trials and other clinical literature, and validated by international experts. Costs and outcomes were estimated using Monte Carlo simulation over a 1-year duration, with costs estimated from the perspective of the National Health Service in Spain. Results: For stimulant-naïve patients without contra-indications to stimulants, the incremental costs per QALY gained for atomoxetine were € 34 308 (compared to an immediate-release MPH) and € 24 310 (compared to an extended-release MPH). For those patients who have stimulant-failure experience or contra-indications to stimulants, the incremental costs per QALY gained of atomoxetine compared to 'no medication' were € 23 820 and € 23 323, respectively. Conclusion: The economic evaluation showed that atomoxetine is an effective alternative across a range of ADHD populations and offers value-for money in the treatment of ADHD.
ACCESSION #
42408643

 

Related Articles

  • Mental health.  // Archives of Disease in Childhood;Apr2006 Supplement, Vol. 91, pA39 

    The article presents abstracts of medical research. They include "Re-Audit of Management of ADHD With Methylphenidate Based on Nice Guidance," "ADHD: Collaborative Between Paediatricians and CAMHS. Does it Work?" and "A Transitional and Adult Service for Patients With ADHD. Responding to the NSF."

  • Just say yes to Ritalin! Diller, Lawrence H. // Human Life Review;Winter2001, Vol. 27 Issue 1, p108 

    Focuses on pressures in the United States to use Ritalin to treat school children with attention deficit hyperactivity disorder. Need to explore other options; Prerequisites to prescribing Ritalin; Concerns over Surgeon General David Satcher's statement about Ritalin being underprescribed.

  • Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD. Toplak, Maggie E. // Evidence Based Mental Health;Feb2009, Vol. 12 Issue 1, p19 

    The article discusses the study "Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response," by J. H. Newcorn, C. J. Kratochvil, A. J. Allen, C. D. Casat, D. D. Ruff, R. J. Moore and D....

  • Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder.  // Annals of General Psychiatry;2011, Vol. 10 Issue 1, p25 

    The article discusses the diagnosis, referral and treatment pathways for patients with attention deficit hyperactivity disorder (ADHD). It notes that there are a number of problems associated with the use of immediate-release preparations of methylphenidate (MPH), that have proven effective in...

  • Does ADHD Even Exist? Breeding, John // Mothering;Jul/Aug2000, Issue 101, p43 

    Focuses on the use of the Ritalin drug as treatment for attention-deficit hyperactivity disorder in the United States. Role of parents and adults in determining psychiatric drug prescription for children; Behavior disorders relieved by the use of Ritalin. INSETS: Suffer the Children?;Ritalin...

  • What About the Dam Break Upstream? Börner, Joachim // Deutsches Aerzteblatt International;12/27/2010, Vol. 107 Issue 51/52, p918 

    A letter to the editor is presented in response to the article "The Changing Prevalence of Attention-Deficit/ Hyperactivity Disorder and Methylphenidate Prescriptions: A Study of Data From a Random Sample of Insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007."

  • Effects of methylphenidate on the academic performance of children with attention-deficit... Carlson, Caryn L.; Bunner, Melissa R. // School Psychology Review;1993, Vol. 22 Issue 2, p184 

    Investigates the effects of psychostimulant medications on learning and achievement in children with attention-deficit hyperactivity disorder. Short- and long-term effects of methylphenidate; Individual differences in response to medication.

  • The impact of recent lawsuits on methylphenidate sales. Safer, Daniel J. // Clinical Pediatrics;Mar1994, Vol. 33 Issue 3, p166 

    Focuses on the impact of lawsuits concerning alleged misuse of methylphenidate (Ritalin) treatment for hyperactivity in children. Background information; Effect on sales; Examination of government records and estimated sales; Media campaign by various groups; Intimidating aspects of lawsuits.

  • Ritalin may influence serotonin balance in hyperactive children. Berger, Abi // BMJ: British Medical Journal (International Edition);01/23/99, Vol. 318 Issue 7178, p212 

    Discusses how methylphenidate or Ritalin may influence serotonin balance in hyperactive children. Effect of the drug in children with attention deficit hyperactivity disorder (ADHD); Result of the research on the effectiveness of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics